Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin saturation; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. In addition, the company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, and handheld capnograph and capnometer devices; and O3 regional oximetry for tissue oxygen saturation measurement. Further, it provides Patient SafetyNet, a surveillance, remote monitoring, and clinician notification solution; MyView, a wireless presence-detection system; and connectivity devices. The company provides its products directly, as well as through distributors and original equipment manufacturers partners to hospitals, emergency medical service providers, physician offices, veterinarians, long term care facilities, and consumers. Masimo Corporation has a strategic partnership with NU Hospitals. The company was founded in 1989 and is headquartered in Irvine, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:MASI
CUSIP57479510
Phone949-297-7000
Debt
Debt-to-Equity RatioN/A
Current Ratio4.55
Quick Ratio3.86
Price-To-Earnings
Trailing P/E Ratio40.64
Forward P/E Ratio34.96
P/E Growth2.37
Sales & Book Value
Annual Sales$798.11 million
Price / Sales6.55
Cash Flow$3.0887 per share
Price / Cash32.71
Book Value$13.68 per share
Price / Book7.39
Profitability
EPS (Most Recent Fiscal Year)$2.45
Net Income$131.61 million
Net Margins15.99%
Return on Equity23.14%
Return on Assets18.33%
Miscellaneous
Employees1,400
Outstanding Shares51,780,000
Market Cap$5,152.09
Masimo (NASDAQ:MASI) Frequently Asked Questions
What is Masimo's stock symbol?
Masimo trades on the NASDAQ under the ticker symbol "MASI."
How were Masimo's earnings last quarter?
Masimo Co. (NASDAQ:MASI) posted its earnings results on Wednesday, May, 2nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.69 by $0.06. The medical equipment provider had revenue of $212.90 million for the quarter, compared to analyst estimates of $205.65 million. Masimo had a return on equity of 23.14% and a net margin of 15.99%. Masimo's revenue for the quarter was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.57 earnings per share. View Masimo's Earnings History.
When is Masimo's next earnings date?
What guidance has Masimo issued on next quarter's earnings?
Masimo issued an update on its FY18 earnings guidance on Wednesday, May, 2nd. The company provided EPS guidance of $2.88 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.81.
What price target have analysts set for MASI?
5 brokers have issued 1-year target prices for Masimo's stock. Their forecasts range from $94.00 to $108.00. On average, they expect Masimo's share price to reach $100.80 in the next year. This suggests that the stock has a possible downside of 0.2%. View Analyst Ratings for Masimo.
What is the consensus analysts' recommendation for Masimo?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Masimo in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Masimo's key competitors?
Some companies that are related to Masimo include SONOVA Hldg AG/ADR (SONVY), Varian Medical Systems (VAR), LivaNova (LIVN), GETINGE AB/ADR (GNGBY), CONMED (CNMD), NxStage Medical (NXTM), AxoGen, Inc Common Stock (AXGN), Natus Medical (BABY), Viewray (VRAY), Cutera (CUTR), BioLife Solutions (BLFS), Vision Sciences (CGNT), Rockwell Medical (RMTI), Fonar (FONR) and Helius Medical Technologies (HSDT).
Who are Masimo's key executives?
Masimo's management team includes the folowing people:
- Mr. Micah Young, Exec. VP of Fin. & CFO (Age 39)
- Mr. Joseph E. Kiani, Founder, CEO & Chairman (Age 53)
- Mr. Anand Sampath, Chief Operating Officer (Age 52)
- Mr. David J. Van Ramshorst, Chief Accounting Officer & Sr. VP of Fin. (Age 57)
- Mr. Yongsam Lee, Exec. VP & Chief Information Officer (Age 53)
Has Masimo been receiving favorable news coverage?
Media headlines about MASI stock have been trending somewhat positive on Tuesday, Accern Sentiment reports. The research group rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Masimo earned a coverage optimism score of 0.08 on Accern's scale. They also assigned headlines about the medical equipment provider an impact score of 45.35 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are Masimo's major shareholders?
Masimo's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Retirement Systems of Alabama (0.35%), Bank of Montreal Can (0.09%), Xact Kapitalforvaltning AB (0.02%), Fox Run Management L.L.C. (0.01%), State of Alaska Department of Revenue (0.01%) and Campbell & CO Investment Adviser LLC (0.01%). Company insiders that own Masimo stock include Anand Sampath, Joe E Kiani, Jon Coleman, Paul Jansen, Raad Mark De, Ramshorst David J Van, Rick Fishel, Sanford Fitch, Steven Barker, Thomas Samuel Mcclenahan and Yongsam Lee. View Institutional Ownership Trends for Masimo.
Which major investors are selling Masimo stock?
MASI stock was sold by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C.. Company insiders that have sold Masimo company stock in the last year include Jon Coleman, Ramshorst David J Van, Sanford Fitch, Steven Barker and Yongsam Lee. View Insider Buying and Selling for Masimo.
Which major investors are buying Masimo stock?
MASI stock was purchased by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, State of Alaska Department of Revenue, Raymond James Trust N.A., Matisse Capital, Xact Kapitalforvaltning AB, Cerebellum GP LLC, Campbell & CO Investment Adviser LLC and Bank of Montreal Can. View Insider Buying and Selling for Masimo.
How do I buy shares of Masimo?
Shares of MASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Masimo's stock price today?
One share of MASI stock can currently be purchased for approximately $101.03.
How big of a company is Masimo?
Masimo has a market capitalization of $5.15 billion and generates $798.11 million in revenue each year. The medical equipment provider earns $131.61 million in net income (profit) each year or $2.45 on an earnings per share basis. Masimo employs 1,400 workers across the globe.
How can I contact Masimo?
Masimo's mailing address is 52 DISCOVERY, IRVINE CA, 92618. The medical equipment provider can be reached via phone at 949-297-7000 or via email at [email protected]
MarketBeat Community Rating for Masimo (NASDAQ MASI)
MarketBeat's community ratings are surveys of what our community members think about Masimo and other stocks. Vote "Outperform" if you believe MASI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MASI will underperform the S&P 500 over the long term. You may vote once every thirty days.
